Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994
   Google Scholar
• World Health Organization. International classification of diseases. 10th Revision (ICD-10) World Health Organization, Geneva, Switzerland; 1992
   Google Scholar
• WHO global report: mortality attributable to tobacco. 2012. ISBN: 978 92 4 156443 4. Available from: http://www.who.int/tobacco/publications/surveillance/rep_mortality_attributable/en/index.html [Last accessed 27 February 2013]
   Google Scholar
• Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 2009;9(9):655-64
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observation on male British doctors. BMJ 2004;328(7455):1519
   PubMed Web of Science ®Google Scholar
• Pirie K, Peto R, Reeves GK, et al. Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013;381(9861):133-41
   PubMed Web of Science ®Google Scholar
• Raw M. Framework convention on tobacco control (FCTC) article 14 guidelines: a new era for tobacco dependence treatment. Addiction 2011;106(12):2055-7
   PubMed Web of Science ®Google Scholar
• West R, McNeill A, Britton J, et al. Should smokers be offered assistance with stopping? Addiction 2010;105(11):1867-9
   PubMed Web of Science ®Google Scholar
• Chapman S, Wakefield M. Smoking cessation strategies. BMJ 2012;344:e1732
   Web of Science ®Google Scholar
• Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010;7(2):e1000216
   PubMed Web of Science ®Google Scholar
• Chapman S. The inverse impact law of smoking cessation. Lancet 2009;373(9665):701-3
   PubMed Web of Science ®Google Scholar
• Richard P, West K, Ku L. The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS One 2012;7(1):e29665
   Web of Science ®Google Scholar
• Taylor M, Leonardi-Bee J, Agboola S, et al. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction 2011;106(10):1819-26
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Coleman CI, Sobieraj DM. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract 2012;66(2):171-82
   PubMed Web of Science ®Google Scholar
• Murray RL, Bauld L, Hackshaw LE, McNeill A. Improving access to smoking cessation services for disadvantaged groups: a systematic review. J Public Health (Oxf) 2009;31(2):258-77
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine addiction. N Engl J Med 2010;362(24):2295-303
   PubMed Web of Science ®Google Scholar
• The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel L, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35(2):158-76
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012(11):CD000146
   Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007(1):CD000031
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012(4):CD006103
   Google Scholar
• Etter JF, Schneider NG. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. Nicotine Tob Res 2013;15(1):59-68
   PubMed Web of Science ®Google Scholar
• Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009;11(11):1265-73
   PubMed Web of Science ®Google Scholar
• George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 2008;83(4):619-21
   PubMed Web of Science ®Google Scholar
• Berlin I, Saïd S, Spreux-Varoquaux O, et al. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995;38:756-61
   PubMed Web of Science ®Google Scholar
• Hughes JR. An updated algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat 2013;45(2):215-21
   PubMed Web of Science ®Google Scholar
• West RJ, Jarvis MJ, Russell MA, et al. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 1984;79(2):215-19
   PubMedGoogle Scholar
• Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an Internet survey. Drug Alcohol Rev 2013;32(2):133-40
   PubMed Web of Science ®Google Scholar
• Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction 2011;106(11):2017-28
   PubMed Web of Science ®Google Scholar
• Dawkins L, Turner J, Roberts A, Soar K. 'Vaping' profiles and preferences: an online survey of electronic cigarette users. Addiction 2013;108(6):1115-25
   PubMed Web of Science ®Google Scholar
• Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008;121(4 Suppl 1):S20-31
   PubMed Web of Science ®Google Scholar
• Foulds J, Burke M, Steinberg M, et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004;9(1):39-53
   PubMedGoogle Scholar
• Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis 2003;7(9):811-19
   PubMed Web of Science ®Google Scholar
• Tønnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012;40(3):548-54
   PubMed Web of Science ®Google Scholar
• Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open 2012;2(5):e001618
   Web of Science ®Google Scholar
• Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009(1):CD006219
   Google Scholar
• Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024
   PubMed Web of Science ®Google Scholar
• Staner L, Luthringer R, Dupont C, et al. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 2006;7(2):147-54
   PubMed Web of Science ®Google Scholar
• Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008;3(1):45-53
   PubMedGoogle Scholar
• Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-7
   PubMed Web of Science ®Google Scholar
• Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 2006;6(7):965-81
   PubMedGoogle Scholar
• Gonzales D, Bjornson W, Durcan MJ, et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 2002;22(4):234-9
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Lebargy F, Berlin I, et al. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 2004;99(9):1206-18
   PubMed Web of Science ®Google Scholar
• Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012(1):CD006219
   Google Scholar
• Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002;62(Suppl 2):45-52
   PubMed Web of Science ®Google Scholar
• Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003;24(10):946-55
   PubMed Web of Science ®Google Scholar
• Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357(9268):1571-5
   PubMed Web of Science ®Google Scholar
• Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011;6(11):e27016
   PubMed Web of Science ®Google Scholar
• Wightman DS, Foster VJ, Krishen A, et al. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry 2010;12(5; pii:PCC.09m00894
   PubMedGoogle Scholar
• Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-94
   PubMed Web of Science ®Google Scholar
• Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008;24(7):1931-41
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63(8):717-24
   PubMed Web of Science ®Google Scholar
• Brose LS, West R, Stapleton JA. Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc 2013;88(3):226-33
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009;32(2):119-35
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Wyatt KD, Hays JT, et al. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 2010;4:355-62
   PubMed Web of Science ®Google Scholar
• Potts LA, Garwood CL. Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm 2007;64(13):1381-4
   PubMed Web of Science ®Google Scholar
• FDA. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Saf Newsl 2009.2(1). Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm [Last accessed 30 April 2013; cited 1 October 2010]
   Google Scholar
• Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33(4):289-301
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
   PubMed Web of Science ®Google Scholar
• Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000058
   PubMedGoogle Scholar
• Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365(13):1193-200
   PubMed Web of Science ®Google Scholar
• Vinnikov D, Brimkulov N, Burjubaeva A. A doubleblind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smoking Cessation 2008;3(1):57-62
   Google Scholar
• Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995;58(4):444-52
   PubMed Web of Science ®Google Scholar
• Berlin I, Aubin HJ, Pedarriosse AM, et al. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 2002;97(10):1347-54
   PubMed Web of Science ®Google Scholar
• Weinberger AH, Reutenauer EL, Jatlow PI, et al. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010;107(2–3):188-95
   PubMed Web of Science ®Google Scholar
• Killen JD, Fortmann SP, Murphy GM Jr, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010;105(9):1660-8
   PubMed Web of Science ®Google Scholar
• Berlin I, Hunneyball IM, Greiling D, et al. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology (Berl) 2012;223(1):89-98
   PubMed Web of Science ®Google Scholar
• Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009;5(4):200-5
   PubMed Web of Science ®Google Scholar
• Tonstad S, Heggen E, Giljam H, et al. Niccine(R), a Nicotine Vaccine, for Relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Jackson A, Nesic J, Groombridge C, et al. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 2009;34(2):257-65
   PubMed Web of Science ®Google Scholar
• Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010;71(5):634-48
   PubMed Web of Science ®Google Scholar
• Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008;103(4):687-94
   PubMed Web of Science ®Google Scholar
• Baltieri DA, Daro FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009;105(1-2):33-41
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers. Arch Intern Med 2005;165:1600-5
   PubMed Web of Science ®Google Scholar
• Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009;103(1-2):30-6
   PubMed Web of Science ®Google Scholar
• Evins AE, Pachas G, Mischoulon D, et al. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol 2011;31(5):597-602
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, et al. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011;17(4):211-16
   PubMed Web of Science ®Google Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67(4):554-66
   PubMed Web of Science ®Google Scholar
• Schnoll RA, Wileyto EP, Pinto A, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 2008;98(1–2):86-93
   PubMed Web of Science ®Google Scholar
• Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005;30(4):720-30
   PubMed Web of Science ®Google Scholar
• Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev 2011;30(2):119-23
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. Ending tobacco smoking in Britain. Radical strategies for prevention and harm reduction in nicotine addiction. London: Royal College of Physicians. 2008. Available from: http://www.rcplondon.ac.uk/publications/ending-tobacco-smoking-britain [Last accessed 1 May 2013]
   Google Scholar
• Benowitz NL. Smokeless tobacco as a nicotine delivery device: harm or harm reduction? Clin Pharmacol Ther 2011;90(4):491-3
   PubMed Web of Science ®Google Scholar
• Gray N, Boyle P. The future of the nicotine-addiction market. Lancet 2003;362:845-6
   PubMed Web of Science ®Google Scholar
• Revision of the Tobacco Products Directive of the European Commission. Available from: http://ec.europa.eu/health/tobacco/docs/com_2012_788_en.pdf [Last accessed 2 May 2013]
   Google Scholar
• Kozlowski LT, Strasser AA, Giovino GA, et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control 2001;10(3):201-3
   PubMed Web of Science ®Google Scholar
• Sizemore C. Can E-Cigarettes Relight Big Tobacco? Available from: http://investorplace.com/2013/04/can-e-cigarettes-relight-big-tobacco/ [Last accessed 2 May 2013]
   Google Scholar
• Aubin HJ, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev 2012;36(1):271-84
   PubMed Web of Science ®Google Scholar
• Aubin HJ. Management of emergent psychiatric symptoms during smoking cessation. Curr Med Res Opin 2009;25(2):519-25
   PubMed Web of Science ®Google Scholar
• Etter JF, Bullen C, Flouris AD, et al. Electronic nicotine delivery systems: a research agenda. Tob Control 2011;20(3):243-8
   PubMed Web of Science ®Google Scholar
• Le Houezec J. Nicotine: abused substance and therapeutic agent. J Psychiatry Neurosci 1998;23(2):95-108
   PubMed Web of Science ®Google Scholar